ABT ABBOTT LABORATORIES
Price Chart
Executive Summary
Freedom Broker upgraded Abbott Laboratories (ABT) to Buy from Hold with a $120 price target, down from $130 prior, in a cluster of six firms acting on the stock. The firm has a 66% accuracy rate on 68 calls with an average return of 11.8%. Consensus is heavily bullish: 74% Buy/Strong Buy (26 analysts) versus 26% Hold (9 analysts), with zero sells. The mean target is $118.64, median $120, high $143, low $92 — current price $90.79 implies 30.7% upside. Momentum is flat with zero upgrades/downgrades in 30 days, but EPS revisions are sharply negative: 23 downgrades for the current quarter and 24 for the current year. Cross-platform signals show convergence: insider buying of $1.1M in late April, institutional accumulation (Norges Bank new $2.9B, FMR added 27%), but short interest is elevated at 55% of volume. The upgrade from a mid-tier firm with a price target in line with consensus provides a modest bullish signal, tempered by deteriorating earnings estimates.
Impact Score
Consensus & Targets
Analyst consensus is heavily bullish: 10 Strong Buy, 16 Buy, 9 Hold, 0 Sell, 0 Strong Sell (35 total). That's 74% Buy/Strong Buy, 26% Hold. No bearish ratings. The direction is clearly positive, and Freedom Broker's upgrade aligns with the majority view.
Current price: $90.79. Mean target: $118.64, median: $120, high: $143, low: $92. Implied upside to mean: 30.7%. Freedom Broker's $120 PT is exactly at the median and above the mean. The high target (Barclays at $143) offers 57.5% upside; the low (Mizuho at $92) is just 1.3% above current. The PT cut from $130 to $120 is below the prior mean, suggesting reduced expectations.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-27 | BTIG | reiterate | Buy | $131.00 |
| 2026-04-20 | Barclays | maintain | Overweight | $143.00 |
| 2026-04-17 | Piper Sandler | maintain | Overweight | $115.00 |
| 2026-04-17 | Oppenheimer | maintain | Outperform | $115.00 |
| 2026-04-17 | RBC Capital | maintain | Outperform | $130.00 |
| 2026-04-17 | Benchmark | maintain | Buy | $120.00 |
| 2026-04-17 | Evercore ISI Group | maintain | Outperform | $120.00 |
| 2026-04-17 | B of A Securities | maintain | Buy | $120.00 |
| 2026-04-17 | Stifel | maintain | Buy | $120.00 |
| 2026-04-17 | BTIG | reiterate | Buy | $131.00 |
No rating changes in the last 30 days besides this cluster. EPS revision trend is heavily negative: for the current quarter, 23 downward revisions and 0 upward in 30 days; for the current fiscal year, 24 down vs 0 up. Estimates for Q2 (next quarter) show 21 down vs 1 up. Revisions are accelerating lower even as analyst ratings remain bullish — a divergence that warrants caution.
Firm Track Record — Freedom Broker
Freedom Broker accuracy: 66% on 68 calls | avg return: 11.8%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Citigroup | 67% | 4/6 | 1.2% | top tier |
| Jefferies | 67% | 4/6 | 0.8% | top tier |
| Evercore ISI Group | 63% | 5/8 | 0.8% | top tier |
| RBC Capital | 56% | 5/9 | 1.8% | above average |
| Wells Fargo | 50% | 2/4 | -0.4% | below average |
| Goldman Sachs | 50% | 1/2 | 4.5% | below average |
| Barclays | 50% | 3/6 | 1.1% | below average |
| UBS | 50% | 1/2 | 1.3% | below average |
| Stifel | 50% | 1/2 | -0.9% | below average |
| BTIG | 40% | 2/5 | -3% | below average |
Freedom Broker has been correct on 66% of 68 calls with an average return of 11.8%. Among firms covering ABT, Citigroup and Jefferies lead with 67% accuracy (on 6 calls each). The worst performers are Piper Sandler, Morgan Stanley, and Bernstein (0% accuracy on 3 calls each, negative average returns). Freedom Broker's track record is above the median for this ticker and notably better than the 0% firms.
Earnings Estimates
Next earnings: Jul 15, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $5.48 | $5.40 — $5.71 | $50.3B | ↑3 ↓0 |
| +1y | $6.06 | $5.95 — $6.20 | $54.8B | ↑1 ↓0 |
| 0q | $1.28 | $1.26 — $1.29 | $12.5B | ↑0 ↓0 |
| +1q | $1.42 | $1.40 — $1.47 | $13.1B | ↑5 ↓0 |
Cross-Platform Signals
Insider activity is bullish: two large buys in late April totaling $1.13M (CEO Daniel Starks $927k, executive Philip Boudreau $201k) versus only $169k in sells in March. Institutional changes are mixed but lean positive: new $2.9B position by Norges Bank, $70M new by Renaissance Technologies, and FMR adding 27% ($1.8B). Two Sigma and Norges Bank exited earlier. Short interest is very high at 55% of volume (3.07M shares short vs 5.59M in TRF volume) — a squeeze potential if buying persists. Congressional trades are small and mixed (2 buys, 3 sells, amounts under $50k). Overall, insider accumulation and institutional inflows converge with the analyst upgrade, but high short interest and negative earnings revisions create a tug-of-war.
Actionable Insight
The upgrade from a decent firm, combined with recent insider buying and large institutional adds, supports a tactical long entry near $90 — but negative EPS revisions and high short interest require tight stops. Position size with a $108 take-profit (20% upside) and a $84 stop-loss (7% downside).
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 31, 2026
9d ago
|
ANALYST-UPGRADE
| $106.00 $109.09 | ▲ +2.92% | ▲ +5.28% | $91.25 (−13.91%) |
|
May 28, 2026
13d ago
|
Court Ruling
| $86.24 $86.99 | ▲ +0.87% | ▲ +0.92% | $91.25 (+5.81%) |
|
May 1, 2026
5w ago
|
ANALYST-UPGRADE
| $106.00 $109.09 | ▲ +2.92% | ▲ +5.28% | $91.25 (−13.91%) |
|
Apr 27, 2026
6w ago
|
8-K
| $93.83 $87.54 | ▼ −6.70% | ▼ −8.39% | $91.25 (−2.75%) |
|
Apr 23, 2026
6w ago
|
Insider Cluster
| $91.35 $86.22 | ▼ −5.62% | ▼ −8.73% | $91.25 (−0.11%) |
|
Apr 17, 2026
7w ago
|
8-K
| $96.00 $92.83 | ▼ −3.30% | ▼ −4.22% | $91.25 (−4.94%) |
|
Apr 16, 2026
7w ago
|
8-K
| $95.48 $92.43 | ▲ +3.19% | ▲ +4.18% | $91.25 (+4.43%) |
|
Mar 30, 2026
10w ago
|
Court Ruling
| $101.86 $101.79 | ▼ −0.07% | ▼ −4.37% | $91.25 (−10.41%) |
|
Mar 23, 2026
11w ago
|
8-K
| $104.84 $101.86 | ▼ −2.84% | ▲ +0.72% | $91.25 (−12.96%) |
|
Mar 13, 2026
12w ago
|
DEFA14A
| $109.96 $104.84 | ▼ −4.66% | ▼ −2.61% | $91.25 (−17.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access